Search
Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigationalDeuruxolitinib is a deuterated form of ruxolitinib that selectively inhibits Janus kinases (JAK) JAK1 and JAK2. Deuteration allows the drug to circumvent extensive oxidative metabolism around the cyclopentyl ring, which increases the dur...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSunvozertinib
go.drugbank.com/drugs/DB18925InvestigationalSunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. … A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, P-glycoprotein inhibitorsSuzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigationalSuzetrigine is a NaV1.8 voltage-gated sodium channel blocker with analgesic properties NaV1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain signal transmission, making it a desirable therapeutic target for t...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 InducersOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesBaxdrostat
go.drugbank.com/drugs/DB19090ApprovedInvestigationalBaxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLanepitant
go.drugbank.com/drugs/DB19599ExperimentalThe usage of the INN stem '-pitant' in the name indicates that Lanepitant is a neurokinin NK1 (substance P) receptor antagonist. Lanepitant has a monoisotopic molecular weight of 559.35 Da.
Categories: Neurokinin-1 Receptor AntagonistsFosfluconazole
go.drugbank.com/drugs/DB19833ExperimentalFosfluconazole is a small molecule drug. Fosfluconazole has a monoisotopic molecular weight of 386.07 Da.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsDitekiren
go.drugbank.com/drugs/DB19992ExperimentalDitekiren is a small molecule drug. The usage of the INN stem '-kiren' in the name indicates that Ditekiren is a renin inhibitor. Ditekiren has a monoisotopic molecular weight of 929.57 Da.
Categories: P-glycoprotein substratesLascufloxacin
go.drugbank.com/drugs/DB20002ExperimentalLascufloxacin is a small molecule drug. The usage of the INN stem '-oxacin' in the name indicates that Lascufloxacin is a nalidixic acid derivative antibacterial. Lascufloxacin has a monoisotopic molecular weight of 439.17 Da.
Categories: P-glycoprotein substratesCilobradine
go.drugbank.com/drugs/DB20039InvestigationalCilobradine is under investigation in clinical trial NCT02264041 (Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine).